Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials
Cargnin S, Shin J, Genazzani A, Nottegar A, Terrazzino S. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials. Cancer Chemotherapy And Pharmacology 2020, 86: 577-588. PMID: 33005979, DOI: 10.1007/s00280-020-04156-3.Peer-Reviewed Original ResearchConceptsObjective response rateHER2+ breast cancerRandomized Controlled TrialsBreast cancerTrastuzumab biosimilarsMeta-analysisTreatment of HER2+ breast cancerPhase III randomized controlled trialsIntention-to-treat populationMeta-analysis of randomized clinical trialsTreatment-emergent adverse effectsMeta-analysis of randomized controlled trialsRelative riskPurposeTo assess efficacyInfusion-related reactionsPer-protocol populationConclusionThis meta-analysisConfidence intervalsMantel-Haenszel methodMethodsA comprehensive searchRandomized clinical trialsSystematic reviewReference drugOverall survivalNo significant difference
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply